3 Suppliers
9 Customers
3 Debt Items
20 Related Chains
Search SGHT in the supply chain database
Create SGHT supply chain alerts
Read SGHT supply chain intel
ORANGE supply chain
NVIDIA Corporation supply chain
Amazon.com, Inc. supply chain
Johnson & Johnson supply chain
Suppliers 3
Clients 9
Debt 3
Acquisitions 0
Ownership 1
Secondary 20
Sight Sciences, Inc. Suppliers
Ticker Name Confidence Evidence
DEERFIELD-CAMPBELL-LLC
DEERFIELD-CAMPBELL-LLC
90%
The Second Amendment amends that certain Multi-Tenant Space Lease, dated February 5, 2021, and that certain Commencement Date/Acceptance Agreement, dated August 1, 2021, between the Company and Lesso…
JNJ
Johnson & Johnson
72%
Reciprocal relationship from JNJ graph: Reciprocal relationship from SGHT graph: cialize products for eye conditions. Notable competitors with approved MIGS products include Glaukos, Alcon, AbbVie, N…
JNJ
Johnson & Johnson
72%
cialize products for eye conditions. Notable competitors with approved MIGS products include Glaukos, Alcon, AbbVie, New World Medical, and Nova Eye Medical Limited. Notable competitors with approved…
Sight Sciences, Inc. Customers
Ticker Name Confidence Evidence
ALCON-INC
ALCON-INC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
ALCON-RESEARCH-LLC
ALCON-RESEARCH-LLC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
ALCON-VISION-LLC
ALCON-VISION-LLC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
IVANTIS-INC
IVANTIS-INC
92%
The Company had asserted that Alcon’s sale of the Hydrus® Microstent ("Hydrus") infringed three of the Company’s patents.
ASCS
ASCS
90%
We currently derive the majority of our U.S. revenue from the sale of our OMNI and SION products to ASCs and HOPDs
ECPS
ECPS
90%
We currently derive the majority of our U.S. revenue from the sale of our TearCare products to ECPs
HOPDS
HOPDS
90%
We currently derive the majority of our U.S. revenue from the sale of our OMNI and SION products to ASCs and HOPDs
JNJ
Johnson & Johnson
72%
cialize products for eye conditions. Notable competitors with approved MIGS products include Glaukos, Alcon, AbbVie, New World Medical, and Nova Eye Medical Limited. Notable competitors with approved…
JNJ
Johnson & Johnson
72%
Reciprocal relationship from JNJ graph: Reciprocal relationship from SGHT graph: Reciprocal relationship from JNJ graph: Reciprocal relationship from SGHT graph: cialize products for eye conditions. …
Sight Sciences, Inc. Debt Obligations
Instrument Description Confidence Evidence
SGHT-DEBT-12501
Warrants outstanding: 0
90%
xbrl warrant detail from xbrl 2025-12-31.
SGHT-DEBT
Debt stack $41.8M
90%
Market cache reports total debt of $41.8M.
SGHT-DEBT-12502
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2021-09-30.
Sight Sciences, Inc. Acquisitions
No acquisitions on record No completed or pending acquisitions found in our database for Sight Sciences, Inc..
Sight Sciences, Inc. Ownership
Holder Name Confidence Evidence
SGHT-OWNER-LONG-FOCUS-CAPITAL-MANAGEMENT-LL
Long Focus Capital Management, LLC
90%
13F overlay lists Long Focus Capital Management, LLC as top holder; 113 tracked holders.
Sight Sciences, Inc. Extended Supply Chain Network
Ticker Name Chain Index Hops Relationship Types
REPL
Replimune Group, Inc.
100.00
2
ALEC
Alector, Inc.
100.00
2
ENGN
enGene Therapeutics Inc.
100.00
2
RCUS
Arcus Biosciences, Inc.
100.00
2
OBIO
Orchestra BioMed Holdings, Inc.
100.00
2
KURA
Kura Oncology, Inc.
100.00
2
SVRA
Savara Inc.
100.00
2
CMPS
COMPASS Pathways plc
100.00
2
MDGL
Madrigal Pharmaceuticals, Inc.
100.00
2
PHGE
BiomX Inc.
100.00
2
JNJ
Johnson & Johnson
100.00
1
['customer', 'supplier']
MAZE
Maze Therapeutics, Inc.
100.00
2
VRDN
Viridian Therapeutics, Inc.
100.00
2
BCYC
Bicycle Therapeutics plc
100.00
2
DYN
Dyne Therapeutics, Inc.
100.00
2
IRON
Disc Medicine, Inc.
100.00
2
ALT
Altimmune, Inc.
100.00
2
HOPDS
HOPDS
60.75
1
['receiving']
ECPS
ECPS
60.75
1
['receiving']
ASCS
ASCS
60.75
1
['receiving']